We are rapidly translating our specific, efficient and versatile CRISPR/Cas9 gene-editing platform into therapies to treat hemoglobinopathies, cancer, diabetes and other diseases. Our multi-disciplinary team of world-class researchers and drug developers works every day to translate our CRISPR/Cas9 technology into breakthrough human therapeutics. Our lead program targeting the blood diseases β-thalassemia and sickle cell disease has entered clinical testing, as has our first allogeneic CAR-T program targeting B-cell malignancies. We are also advancing additional blood stem cell, immuno-oncology, regenerative medicine and in vivo programs towards the clinic. Source
No articles found.
Neovasc is a specialty medical device company that develops, manufactures and mark...
Neovasc is a specialty medical device company t...
Trinity Biotech specializes in the development, manufacture and marketing of diagn...
Trinity Biotech specializes in the development,...
Count.It connects with wearable tracking devices and apps to power community fitne...
Count.It connects with wearable tracking device...
Mirati Therapeutics (NASDAQ: MRTX) is a San Diego-based clinical-stage biotechnolo...
Mirati Therapeutics (NASDAQ: MRTX) is a San Die...
Headquartered in Bedford, Massachusetts, Anika Therapeutics, Inc. develops, manufa...
Headquartered in Bedford, Massachusetts, Anika ...
As a leading manufacturer of medical devices and components, Atrion makes a wide r...
As a leading manufacturer of medical devices an...
Join the National Investor Network and get the latest information with your interests in mind.